These molecules mostly target neurotransmitters of ascending systems from the brainstem nuclei, and have been directed to treat cognitive impairments of attention deficit hyperactivity disorder (ADHD), Parkinson’s disease, schizophrenia, while acetylcholinesterase inhibitors are currently used as a the therapy in Alzheimer’s disease (Husain and Mehta, 2011). Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.